HR0156LRB100 10139 MST 21975 r

1
HOUSE RESOLUTION

 
2    WHEREAS, Fibromuscular dysplasia (FMD) is a disease that
3causes abnormal cell growth of the arterial wall; it can lead
4to areas of narrowing, beading, aneurysms, and dissections of
5the arterial wall; and
 
6    WHEREAS, Until recently, there has been very little
7progress in understanding the disease since it was first
8diagnosed in 1938; there is no known cause or cure for the
9disease and there are no set protocols to treat the disease;
10and
 
11    WHEREAS, FMD has always been considered and is still
12classified as a rare disease; many researchers now believe FMD
13is an under-diagnosed disease; some of the data suggest that
144-5% of the population may be affected by the disease; and
 
15    WHEREAS, Ninety percent of the patients affected by FMD are
16women, but men and children are also afflicted; there are
17different classifications of FMD; the two most common types are
18medial fibroplasia and intimal fibroplasia; unlike the adult
19population, children tend to be diagnosed with intimal
20fibroplasia, which can be more aggressive; some patients
21present with both types of the disease; there is no
22understanding of why there are differences; and
 

 

 

HR0156- 2 -LRB100 10139 MST 21975 r

1    WHEREAS, Individuals and families affected by
2fibromuscular dysplasia often experience problems such as a
3sense of isolation, difficulty in obtaining accurate and timely
4diagnosis, and optimal treatment options; and
 
5    WHEREAS, The Fibromuscular Dysplasia Society of America
6(FMDSA) was founded in March of 2003; over the past 14 years,
7this association has been active and successful with many
8programs, including public and physician awareness, patient
9support, and engaging with researchers from around the world;
10and
 
11    WHEREAS, The FMDSA is funding the United States Registry
12for Fibromuscular Dysplasia; previously it was thought that 75%
13of FMD cases affected the renal arteries, but recent data has
14proven that to be inaccurate; it is also very common to have a
155-year delay from onset of symptoms to diagnosis; and
 
16    WHEREAS, There is still much needed awareness and research
17of the disease; FMD patients present with many of the same
18complaints as other patients with more common conditions, such
19as hypertension, headaches, and dizziness; others present with
20TIA or stroke, dissection of an artery, aneurysm, swooshing
21noise in the ear, and renal infarction; children can present
22with basic symptoms such as high blood pressure, headaches,

 

 

HR0156- 3 -LRB100 10139 MST 21975 r

1insomnia, fatigue, and abdominal pain; misdiagnoses of FMD can
2lead to severe consequences and disability; and
 
3    WHEREAS, During the month of May each year, the FMDSA
4organizes a global observance of the issues associated with
5fibromuscular dysplasia; patients, medical professionals, and
6researchers join together to focus attention on fibromuscular
7dysplasia as a public health issue; therefore, be it
 
8    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
9HUNDREDTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we
10designate May of 2017 as "Fibromuscular Dysplasia Awareness
11Month" in the State of Illinois; and be it further
 
12    RESOLVED, That a suitable copy of this resolution be
13presented to the Fibromuscular Dysplasia Society of America as
14an expression of our esteem and respect.